Table 3 KEGG pathway analyses of the predicted target genes of the validated most differentially expressed microRNAs with P < 0.05
Pathway | P-value | Genes |
|---|---|---|
Putative targets of the up-regulated miRNAs | ||
  Athways in cancer | 0.044 | WNT5A, TCF7, FGFR3, RALBP1, VHL, TGFBR1, IGF1, CTNNA1, STK4, ITGB1, IGF1R, CBLB, CCND1, HIF1A, CDKN1B, JUN, SOS2, HHIP, WNT9A, PIAS1 |
  Wnt signalling pathway | 0.012 | WNT5A, TBL1XR1, TCF7, ROCK2, PPP2R5D, DKK2, CCND1, SIAH1A, JUN, CAMK2B, WNT9A, PPP3CA, FBXW11 |
  Ubiquitin mediated proteolysis | 0.011 | CUL3, UBE2N, UBE2A, CBLB, UBE3A, VHL, UBE2K, SIAH1A, UBE2I, HERC2, PIAS1, FBXW11 |
  Leukocyte transendothelial migration | 0.037 | GNAI2, ACTN4, ROCK2, CXCR4, RAP1A, RAPGEF4, CTNNA1, ITGB1, CLDN23, PTPN11 |
  Adherens junction | 0.026 | IGF1R, PVRL4, TCF7, TJP1, ACTN4, TGFBR1, CTNNA1, SNAI1 |
  Longterm depression | 0.048 | IGF1R, GNAI2, PLA2G12A, GRID2, IGF1, PRKG2, ITPR2 |
  Ether lipid metabolism | 0.044 | PLA2G12A, PLA2G7, PAFAH1B1, PPAP2A, PPAP2B |
Putative targets of the down-regulated miRNAs | ||
  Ubiquitin mediated proteolysis | 0.003 | CUL3, UBE2N, UBE3A, VHL, RHOBTB2, BIRC6, UBA6, UBE2I, SMURF2, UBE2D1, CUL1 |
  Leukocyte transendothelial migration | 0.017 | CLDN8, ITK, CLDN19, PIK3CA, RAPGEF4, CLDN11, ITGB1, MLLT4, PRKCB |
  T cell receptor signalling pathway | 0.036 | ITK, JUN, PIK3CA, CHP, DDAH1, NFATC3, LCP2, IL2 |
  Long-term depression | 0.042 | GNAO1, IGF1, GUCY1B3, GRM1, ITPR1, PRKCB |